CSBio CSBio

X
[{"orgOrder":0,"company":"Kither Biotech","sponsor":"Claris Ventures","pharmaFlowCategory":"D","amount":"$18.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kither Biotech Raises \u20ac18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Kither Biotech"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.

            Lead Product(s): KIT2014

            Therapeutic Area: Genetic Disease Product Name: KIT2014

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Claris Ventures

            Deal Size: $18.5 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing March 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY